Infectious Disease Antigens and Antibodies: Core Raw Materials Powering Diagnostic and Vaccine Development
05 Mar 2026
Concept
Infectious disease research stands as a cornerstone of global public health governance. Amid the rapid advancement of globalization, the cross-border transmission of infectious pathogens has become faster and more widespread, elevating the research and development of diagnostic tools and preventive vaccines for emerging and re-emerging infectious diseases to a strategic priority in the global health sector.
Antigens and antibodies serve as the core raw materials in this field: pathogenic antigens are the key targets for identifying infectious agents, developing diagnostic immunoassays and designing vaccine candidates, while specific antibodies are critical for serological diagnosis, neutralization assays and the evaluation of vaccine-induced immune responses. The development of high-purity, high-activity and highly specific infectious disease antigen and antibody raw materials is thus indispensable for advancing infectious disease diagnostics and vaccine research, and for building a robust global public health defense system.
Research Frontier
Current research on infectious disease diagnostics and vaccines is focused on the identification of key pathogenic target proteins, the optimization of antigen design strategies and the development of broad-spectrum, high-efficacy vaccine platforms. A major research trend is the precise screening of functional proteins from various pathogens that are involved in viral entry, replication, immune escape and pathogenicity, and their application as core antigens for diagnostic reagent development and vaccine design.
Additionally, innovative vaccine design strategies have emerged as a research hotspot, including broad-spectrum vaccine development targeting conserved antigenic regions, structural optimization of subunit vaccine antigens, nanoparticle-based antigen presentation systems and peptide vaccine design focusing on core epitopes. These strategies aim to address the challenges of pathogen variation, low immunogenicity of traditional antigens and narrow protective spectra, driving the development of next-generation infectious disease vaccines with superior performance.
Key Target Proteins of Major Infectious Pathogens
| Infectious Disease | Core Research Proteins | Protein Functions & Research Priorities |
|---|---|---|
| SARS-CoV-2 | S protein (RBD domain) | Mediates viral host cell binding; core target for vaccine and neutralizing antibody R&D |
| Influenza A (H1N1) | HA protein, NA protein | HA drives viral entry; NA mediates viral release; primary targets for vaccines and antiviral drugs |
| Respiratory Syncytial Virus (RSV) | F protein, G protein | F protein induces viral-membrane fusion; G protein mediates viral adsorption; key for vaccine and drug development |
| Avian Influenza | HA protein, NA protein | Core antigens for broad-spectrum vaccine development and antiviral research |
| Monkeypox (MPXV) | A35R, A29, B6R, H3L, M1R | Regulate viral replication, immune escape and cellular entry; critical targets for antiviral drug R&D |
| Influenza B | HA protein, NA protein | Key antigens for seasonal vaccine development and antiviral therapy |
| Hepatitis B (HBV) | HBsAg, HBcAg, HBeAg | HBsAg is the main vaccine component; HBcAg/HBeAg associated with viral replication and immune escape |
| HIV | gp120, gp41 | gp120 mediates host cell binding; gp41 induces membrane fusion; core targets for vaccines and neutralizing antibodies |
| Dengue Fever (DENV) | E protein, NS1 protein, NS3 protein | E protein drives viral entry; NS1 linked to severe disease; NS3 involved in viral replication |
| Human Papillomavirus (HPV) | L1 protein, L2 protein | L1 is the core for VLP vaccine development; L2 associated with immune escape and novel vaccine design |
Research Significance
The development and application of high-quality infectious disease antigen and antibody raw materials have far-reaching scientific and translational significance for global public health, infectious disease prevention and control, and biomedical research:
- Advancing infectious disease diagnostics: Specific and high-sensitivity antigen and antibody raw materials are the core of serological diagnostic assays (e.g., ELISA, chemiluminescence, immunochromatography), enabling early, rapid and accurate detection of pathogenic infections, which is critical for epidemic surveillance and clinical diagnosis.
- Accelerating vaccine R&D: Defined pathogenic antigens are the foundation of vaccine design, and specific antibodies are essential for evaluating vaccine immunogenicity and neutralizing efficacy, shortening the vaccine development cycle and improving the success rate of clinical translation.
- Supporting pathogenic mechanism research: Purified infectious disease antigens and specific antibodies provide key research tools for elucidating pathogen entry, replication and immune escape mechanisms, deepening the understanding of infectious disease pathogenesis.
- Strengthening global epidemic response capacity: The availability of standardized, high-quality antigen and antibody raw materials ensures the rapid production of diagnostic reagents and vaccine candidates during sudden epidemic outbreaks, enabling timely and effective global epidemic control.
- Driving the development of biomedical industry: The demand for infectious disease antigen and antibody raw materials promotes technological innovation in protein expression, antibody preparation and immunoassay development, boosting the development of the in vitro diagnostic (IVD) and biopharmaceutical industries.
Related Product Applications
ANT BIO PTE. LTD.’s Starter sub-brand offers a comprehensive portfolio of high-quality infectious disease antigen and antibody raw materials, covering the key target proteins of major infectious pathogens that are the focus of global research. These products are rigorously validated for purity, activity and specificity, and are widely applied in core research and industrial scenarios of infectious disease diagnostics and vaccine development:
- Diagnostic reagent development: High-purity pathogenic antigens and specific monoclonal/polyclonal antibodies are used as core raw materials for the production of IVD assays, enabling the development of high-sensitivity and high-specificity diagnostic kits for infectious disease screening, confirmation and prognosis assessment.
- Vaccine R&D and evaluation: Functional pathogenic antigens serve as core candidates for vaccine design (e.g., subunit vaccines, VLP vaccines, nanoparticle vaccines); specific neutralizing antibodies are used to evaluate the in vitro and in vivo neutralizing efficacy of vaccine candidates, providing critical data for vaccine optimization.
- Pathogenic mechanism research: Purified recombinant pathogenic proteins and specific antibodies are essential tools for studying pathogen-host cell interaction, viral replication and immune escape mechanisms, supporting the identification of novel therapeutic targets.
- Serological surveillance and epidemiological research: Specific antibody raw materials enable large-scale serological surveys of infectious diseases, clarifying the population immunity level and epidemic transmission characteristics, providing a scientific basis for public health decision-making.
- Antiviral drug screening: Pathogenic antigens involved in key biological processes (e.g., viral entry, replication) are used as screening targets for antiviral drugs, enabling the rapid identification of small molecule or antibody-based antiviral candidates.
In addition, ANT BIO PTE. LTD.’s Absin and UA sub-brands provide complementary life science research reagents to support the full research workflow of infectious disease studies: Absin offers a full range of general life science reagents and immunoassay kits for experimental detection and analysis, while UA provides high-purity recombinant proteins and enzyme reagents for antigen expression, protein interaction studies and in vitro functional assays.
Related Product List
ANT BIO PTE. LTD.’s Starter sub-brand offers a comprehensive range of infectious disease antigen and antibody raw materials, covering the key target proteins of major infectious pathogens as shown in the above table. All products are produced with advanced expression systems (E.coli, Baculovirus-Insect Cells, Mammalian Cells) and undergo strict quality control to ensure high purity, high activity and high specificity.
Key product categories include:
- SARS-CoV-2 Antigens & Antibodies (S protein, RBD domain, neutralizing antibodies)
- Influenza A/B Antigens & Antibodies (HA protein, NA protein)
- RSV Antigens & Antibodies (F protein, G protein)
- Monkeypox (MPXV) Antigens (A35R, A29, B6R, H3L, M1R)
- HBV Antigens & Antibodies (HBsAg, HBcAg, HBeAg)
- HIV Antigens (gp120, gp41)
- DENV Antigens & Antibodies (E protein, NS1 protein, NS3 protein)
- HPV Antigens (L1 protein, L2 protein)
For detailed product specifications, pricing and stock information, please contact our professional technical support team for personalized product solutions.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
